The value of rituximab treatment in primary Sjögren's syndrome

Verstappen, Gwenny M; Nimwegen, Jolien F. van; Vissink, Arjan; Kroese, Frans G. M.; Bootsma, Hendrika

doi:10.1016/j.clim.2017.05.002

Cited by 54 publications

(36 citation statements)

References 64 publications

(126 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Biological treatment has attracted significant attention recently. B cell depletion therapy with rituximab has shown beneficial effects on glandular morphology, dryness and several extraglandular manifestations in patients with pSS . Regarding IL‐17, monoclonal antibodies targeting IL‐17 or the IL‐17 receptor have proven effective in alleviating the course of psoriasis, inflammatory bowel disease and arthritis, but have not yet been applied in patients with pSS .…”

Section: Discussionmentioning

confidence: 99%

“…B cell depletion therapy with rituximab has shown beneficial effects on glandular morphology, dryness and several extraglandular manifestations in patients with pSS. 84 Regarding IL-17, monoclonal antibodies targeting IL-17 or the IL-17 receptor have proven effective in alleviating the course of psoriasis, inflammatory bowel disease and arthritis, but have not yet been applied in patients with pSS. 3 The evidence provided by this meta-analysis suggests that IL-17 is aberrantly expressed in pSS and correlated with disease severity, which could provide a theoretical basis for the development and application of therapies targeting IL-17 for the treatment of pSS.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of interleukin‐17 in primary Sjögren's syndrome and the correlation with disease severity: A systematic review and meta‐analysis

et al. 2018

View full text Add to dashboard Cite

The aberrant expression of interleukin-17 (IL-17) has been reported in primary Sjögren's syndrome (pSS). Abnormalities in IL-17 can promote the production of pro-inflammatory cytokines and aggravate autoimmune disorders. The aim of this study was to investigate alterations of IL-17 in patients with pSS and explore the correlation between IL-17 and disease severity. Eight databases were searched for original studies reporting the expression of IL-17 in patients with pSS and controls. Eligible reports were included in the pooled analysis, and subgroup evaluations were performed according to different types of controls and IL-17 measurement methods. Newcastle-Ottawa Scale criteria were used to assess the risk of bias of the included studies. In total, 45 articles are included in the meta-analysis. The expression of IL-17 is significantly increased in patients with pSS compared to controls. Furthermore, patients with pSS without immunosuppressive treatment show markedly higher IL-17 levels. In addition, patients with pSS with positive rheumatoid factors tend to express a higher level of IL-17 than patients with negative rheumatoid factors. Negative correlations between IL-17 levels and ocular parameters are also found in patients with pSS. The results are similar after adjustment by "trim and fill" methods. In conclusion, the expression of IL-17 is obviously increased in patients with pSS, especially among those without immunosuppressive treatment. In addition, IL-17 level correlates with the disease severity of pSS. These findings demonstrate the significance of IL-17 overexpression in patients with pSS and may provide insights for the development of therapeutic interventions targeting IL-17 for pSS.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Expression of interleukin‐17 in primary Sjögren's syndrome and the correlation with disease severity: A systematic review and meta‐analysis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Although preliminary open label and controlled pilot trials on rituximab therapy for pSS have shown improvement in selected subjective and objective parameters, two large randomized control trials failed to reach the primary end points that were mainly represented by improvement of fatigue and sicca complaints. In contrast with these poor results, it has been clearly shown that rituximab therapy is effective in reducing the level of some serological markers of the disease, such as immunoglobulin M–rheumatoid factor, gammaglobulins, and B‐cell number also in glandular infiltrates . Different hypotheses have been raised to explain these negative results.…”

Section: Introductionmentioning

confidence: 99%

Gene Expression Profiles in Primary Sjögren's Syndrome With and Without Systemic Manifestations

Vitali

Dolcino

Papa

et al. 2019

ACR Open Rheumatology

View full text Add to dashboard Cite

ObjectiveTo investigate the gene expression profile in patients with Sjögren's syndrome that is characterized by different clinical phenotypes.Methods RNA from peripheral blood mononuclear cells was purified in 8 patients with glandular features (GFs) and widespread pain (WP) and 11 with extraglandular manifestations (EGMs) and then was analyzed by hybridization on a human gene chip exploring more than 40,000 human genes. Differentially expressed genes (DEGs) in the two subgroups (ie, those with false discovery rate–corrected P values ≤ 0.01) with respect to 20 healthy controls have been submitted to functional classification using a Gene Ontology database and were mapped to define the networks of protein to protein interactions (PPIs).ResultsThe enriched pathway analyses of DEGs and of the highly interconnected modules identified in the PPI networks showed that the pathological processes characterizing the two subgroups were substantially different. The predominant pathways in patients with EGMs are related to T‐ and B‐cell activation, Toll‐like receptor, interferon signaling, and apoptosis. Conversely, pathological processes related to pain transmission and modulation are preferentially operative in patients with GFs and WP. These data suggest that a neuroinflammatory pathway driven by cytokines and chemokines may play a central role in triggering WP features in this phenotype of patients.ConclusionThe present study supports the hypothesis that different biological pathways are operative in patients with primary Sjögren's syndrome with different clinical phenotypes. A better knowledge of these specific processes might help in tailoring more effective target therapies.

show abstract

“…The workflow described herein can be used for molecular profiling of RFs in patients with rheumatoid arthritis and other systemic autoimmune diseases, and readily adapted for targeted detection of other systemic autoantibodies. Furthermore, RF heavy‐chain molecular biomarkers hold promise for the monitoring of individual RF responses to conventional and biologic therapies for primary SS . Given that RF is an independent predictor of lymphoma in patients with primary SS , it will be interesting to sequence serum RFs to search for associations with particular Ig V H expression profiles and mutational patterns in patients progressing from initial presentation to MC and to lymphoma.…”

Section: Discussionmentioning

confidence: 99%

Molecular Profiling and Clonal Tracking of Secreted Rheumatoid Factors in Primary Sjögren's Syndrome

Wang

Reed

Colella

et al. 2018

Arthritis & Rheumatology

View full text Add to dashboard Cite

show abstract

The value of rituximab treatment in primary Sjögren's syndrome

Cited by 54 publications

References 64 publications

Expression of interleukin‐17 in primary Sjögren's syndrome and the correlation with disease severity: A systematic review and meta‐analysis

Expression of interleukin‐17 in primary Sjögren's syndrome and the correlation with disease severity: A systematic review and meta‐analysis

Gene Expression Profiles in Primary Sjögren's Syndrome With and Without Systemic Manifestations

Molecular Profiling and Clonal Tracking of Secreted Rheumatoid Factors in Primary Sjögren's Syndrome

Contact Info

Product

Resources

About